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COMMENT
Quantification of biomarker functionality predicts patient
outcomes
Banafshé Larijani 1,2,3, James Miles1,2,3,4, Stephen G. Ward5 and Peter J. Parker6,7
Implementation of a quantitative molecular imaging method (iFRET), which determines receptor–ligand interactions, has led to the
finding that patients with a low extent of PD-1/PD-L1 interaction in metastatic NSCLC, and malignant melanoma, display
significantly worsened overall survival compared to those with a high level of interaction.
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The hallmarks of cancer described by Hanahan and Weinberg
illustrate the necessary conditions for the manifestation of
malignant neoplastic diseases.1 One of these conditions is the
evasion of immune-detection and avoidance of immune destruc-
tion. A mechanism by which cancers may evade immune-
surveillance is dysregulation of inhibitory immune-checkpoints.
Immune-checkpoints are comprised of inhibitory receptors, found
on the cell surface of immune-cells, and cognate ligands,
expressed on antigen presenting cells. The programmed death
receptor 1 (PD-1) is an example of an immune-checkpoint
receptor. When engaged with is complementary ligand, pro-
grammed death receptor ligand 1 (PD-L1), there is a reduction of
immune activation. This is in part thought to be facilitated by the
recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to the
ITSM of PD-1.2 Cancers may dysregulate this checkpoint by
upregulating PD-L1, thus facilitating an evasion of immune
surveillance and destruction by tumour-specific T lymphocytes.
Currently, monoclonal antibodies can be used to block PD-1/
PDL-1 interactions, thus restoring immune-mediated tumour
detection and destruction. Whilst these therapies have shown
promising therapeutic benefit, low response rates are encoun-
tered. In a recent study of NSCLC patients, those with a tumour
proportion score of 50% or more exhibited increased response to
pembrolizumab. However, only a 41% response rate was achieved
in this cohort.3 To select patients who are likely to benefit from
these treatments, a number of immunohistochemistry (IHC)-based
assays are used to assess PD-L1 expression, in effect using ligand
expression as a surrogate of checkpoint engagement. This indirect
determination of checkpoint function has not proved effective in
stratifying patients into treatment groups.
A recent study assessed the efficacy of anti-PD-1/PD-L1
therapies in lung carcinoma, renal carcinoma and melanoma. In
this study, patients’ PD-L1 expression was assessed and patients
were classified as PD-L1 positive or PD-L1 negative. Here,
therapeutic benefit was seen in PD-L1 negative patients, implying
that ligand expression is not a suitable biomarker to select
patients for immune-checkpoint therapies.4 Hence, in order to
overcome the shortcomings of IHC-based assays we developed a
molecular imaging assay which quantifies PD-1/PD-L1 interaction
states, alongside receptor and ligand expression (Fig. 1a).5 This
assay is termed iFRET. Alternative assays exist which attempt to
measure PD-1/PD-L1 interaction, however unlike iFRET these
report on distances that likely reflect juxtaposition and cannot be
relied upon to accurately report on checkpoint receptor engage-
ment. For example, others have previously used an imaging
algorithm which determines when PD-1+ and PD-L1+ cells are in
close proximity (≤20 μm).6 However, these distances are greater
than the diameter of a cell. By comparison, iFRET reports events at
the 1–10 nm scale and can directly measure intercellular protein-
protein interactions.
The aforementioned iFRET assay was first compared with the
Roche Ventana SP142 assay which is currently used to assess
clinical PD-L1 expression. Crucially, the iFRET assay was able to
detect a PD-1/PD-L1 interaction in 10 of the 11 PD-L1 negative
ccRCC patients.5 This demonstrates that ligand expression is a
poor surrogate of receptor engagement and that the direct
functional PD-1/PD-L1 interaction needs to be quantified. Follow-
ing this analysis, iFRET was used to assess PD-1/PD-L1 interaction
states in 176 malignant melanoma patients with known clinical
outcomes. One hundred and fifty-nine of these patients were
assessed by IHC methods to determine their PD-L1 expression
profiles. Of the 159 patients, 117 were PD-L1 negative and 42 were
PD-L1 positive. In the PD-L1 negative group, 58 patients showed
checkpoint interaction and 19 of 42 PD-L1 positive group showed
no interaction state.5 This once again highlights the need for
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direct assessment of checkpoint interaction, and subsequent
functionality, rather than indirect determination through the
surrogate of ligand expression. Current methods are creating a
scenario wherein patients may be enduring the side-effects of
immune-checkpoint inhibition to gain no therapeutic benefit.
Conversely, patients may miss these novel treatment opportu-
nities which can potentially deliver increased survival rates.
As patient survival is often correlated to biomarker expression, a
potential correlation between PD-1/PD-L1 and overall survival was
assessed. We demonstrated firstly in melanoma that PD-L1
expression did not correlate to overall survival (p= 0.87) (Fig. 1b).
Conversely, patient’s PD-1/PD-L1 interaction state correlated with
overall survival (p= 0.05). Here, those with a lower PD-1/PD-L1
interaction state experienced a significantly worsened overall
survival (Fig. 1b).5 Following this, PD-1/PD-L1 interaction states
were quantified in a cohort of anti-PD-1 treated metastatic NSCLC
patients. As observed in the melanoma cohort, PD-L1 expression
did not correlate with overall survival. In this NSCLC post-
treatment cohort, those with a lower PD-1/PD-L1 interaction state
again had a significantly worsened overall survival (p= 0.05).5
Current literature suggests that an increase in PD-1/PD-L1
interaction would cause a decrease in overall survival due to
immune-suppression. However, the aforementioned results sug-
gest that in the cohorts examined, a higher interaction state may
correlate with improved survival. It is surmised that a high PD-1/
PD-L1 interaction state infers tumour selection within patients,
resulting in a subset of patients whose tumour facilitate immune-
evasion via PD-1/PD-L1 interaction. It is this subset of patients who
iFRET quantifies PD-1/PD-L1 interaction state in non-small cell lung cancer.
In this sample, a FRET efficiency of 24.12% is detected, which indicates a PD-1/PD-L1 distance of 7.06 nm.
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Fig. 1 iFRET quantifies PD-1/PD-L1 interaction state with patient outcome in malignant melanoma and NSCLC. a iFRET, a two-site assay
simultaneously labels PD-1 and PD-L1 in patient samples. This allows the detection and quantification of PD-1 and PD-L1 interaction,
alongside receptor and ligand expression. The black and white intensity maps show PD-1 and PD-L1 expression in an FFPE NSCLC sample. The
pseudocolour lifetime map indicates FRET occurring between the labelled PD-1 receptor and PD-L1 ligand. This is correlated to a FRET
efficiency of 20.77% and a receptor–ligand distance of 7.29 nm. b iFRET correlates PD-1/PD-L1 interaction state with overall survival in
malignant melanoma. (Top) Kaplan–Meier curve indicates that patients with a higher PD-1/PD-L1 interaction have a significantly worsened
overall survival (p= 0.05, χ2= 3.914). (Bottom) Kaplan–Meier curve correlates overall survival with PD-L1 expression. Here, PD-L1 expression
does not correlate with patient outcome (p= 0.87, χ2= 0.027). Modified from Sanchez-Magraner et al.5.
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are predicted to respond to anti-PD-1/PD-L1 therapies and
possibly should be considered for these treatments. Moreover, it
remains unknown what extent of PD-1/PD-L1 disengagement is
required to increase immune-mediated tumour destruction by
tumour infiltrating lymphocytes.
As the pharmacodynamics of immune-checkpoint interactions
are not monitored, it could be that only a partial or transient
disengagement of PD-1/PD-L1 is required to observe an improved
clinical outcome. It would be beneficial therefore to use iFRET to
assess checkpoint interaction over time to observe how these
checkpoint interactions evolve after treatment. It could be that the
use of anti-PD-1 therapeutic antibodies results in a thresholding of
T lymphocytes. In this instance, after treatment with anti-PD-1
therapies, a subset of T lymphocytes undergo reactivation and are
polarised towards the tumour via recognition of tumour antigens.
The increase of patient survival in those with a high interaction
state may highlight that only a partial reactivation of T
lymphocytes is needed to re-mount an immune response.
Those patients with a low level of interaction and worsened
survival may nevertheless benefit from alternative immune
therapies. These tumours may evade the immune system by
dysregulating CTLA-4/CD-80 or other immune-checkpoint inter-
actions. Furthermore, no tumour will discretely dysregulate one
pathway, in fact, a tumour may evolve to evade host immune
response by modulating multiple pathways simultaneously,
indicating a patient group who would benefit from dual
checkpoint inhibitor therapies.7,8 In these instances, the function-
ality of multiple biomarkers should be quantified simultaneously
in order to tailor patients to the most efficacious therapies.
The approach developed can be regarded as a companion
diagnostic tool and can be utilised alongside routine IHC PD-L1
analysis using sections from the same fixed biopsies. In a wider
context, this approach can be used to determine biomarker
functionality to identify novel predictive biomarkers in a range of
pathologies.
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